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Background
Th  e osteoblast-secreted receptor of activated NF-κB 
(RANK) ligand (RANKL) activates RANK receptors on 
osteoclasts to promote their diﬀ  erentiation, maturation 
and survival, and bone resorption [1]. More recently, 
these same molecules have become clearly implicated in 
the regulation of normal mammary development and 
tumori  genesis [2]. Whereas RANK is constitutively 
present within the mammary glands of mice, the local 
expression of RANKL is tightly coordinated with 
pregnancy-induced expansion of the mammary 
epithelium during lobulo-alveologenesis [3-5]. Several of 
the same hormones that promote this development, 
including progesterone, prolactin and parathyroid 
hormone related protein, also induce RANKL expression 
in the mammary glands, speciﬁ   cally in the mammary 
epithelium [3,4]. Hence, RANKL clearly ﬁ  ts the bill of a 
hormone-induced local growth factor that mediates 
lobulo-alveolar expansion in the mammary gland. 
Indeed, both female RANK and RANKL knockout mice 
do not lactate due to failed lobulo-alveolar development 
during pregnancy [3]. Th   is RANK- and RANKL-
mediated development reﬂ  ects both cell proliferation and 
survival [3,6,7], which are both processes that are crucial 
during mammary tumorigenesis. Correspondingly, 
RANK is expressed by a number of breast cancer cell 
lines, primary breast tumors and local breast lymph node 
metastases [2], lending strong support to a role for 
RANK/RANKL in breast cancer progression and 
metastasis.
Articles
Two recent reports [8,9] now shed important light on a 
role for RANK and RANKL during hormone-initiated 
tumorigenesis. Both studies combined progestin 
exposure (using the stable medroxyprogesterone acetate 
(MPA)) and the chemical mutagen dimethybenz[a]
anthracene (DMBA) with either loss- [9] or gain-of-
function [8] for RANK signaling. Consistent with a 
crucial role for RANK signaling, the onset, incidence and 
invasiveness of tumors induced by MPA/DMBA was 
reduced in RANKmam  mice lacking the receptor in 
mammary epithelial cells [9]. Conversely, mice over-
expressing RANK under control of the mouse mammary 
tumor virus (MMTV) promoter had an increased 
incidence of pre-neoplastic lesions and tumors [8]. 
Likewise, administering RANK-Fc to antagonize RANKL 
decreased the total number of mammary tumors, pre-
neoplastic lesions and the proliferation of both normal 
mammary epithelial cells and those in pre-neoplastic 
lesions [8]. Th  e  eﬀ  ects of MPA-induced RANKL-RANK 
signaling in these studies were manifest as increased cell 
proliferation and protection from apoptosis following 
DMBA-induced DNA damage [9]. RANKL also 
stimulated anchorage-independent growth of SKBr3 cells 
in vitro [9]. Moreover, tumor-initiating cells from 
RANKmam mice were unable to self renew [9] while, in the 
same way, epithelial cells from MMTV-RANK mice 
underwent inappropriate proliferation into the luminal 
cavity of three-dimensional acini [8]. From these results 
both groups concluded that RANK-RANKL induces 
changes consistent with transformation, a proposal that 
will beneﬁ  t from more extensive validation.
Viewpoint
Activation of the progesterone receptor (PR) that is 
present in a subset of epithelial cells within the mammary 
glands of mice [10] stimulates those same cells to produce 
and secrete RANKL [11]. Recently, Brisken and colleagues 
[12] demonstrated that progesterone initiates two waves 
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© 2011 BioMed Central Ltdof epithelial proliferation in the mammary glands. A ﬁ  rst, 
cyclin D1-dependent wave occurred in PR-positive cells 
and was RANKL-independent. Th  e second round of 
cyclin D1-independent proliferation that occurred 
beyond 48 hours in PR-negative cells was then RANKL-
dependent [12]. Th   is chronology of progesterone-
induced proliferation and RANKL secretion supports the 
model that PR-positive cells stimulate proliferation in 
adjacent PR-negative cells by a paracrine mechanism 
[10], within which there is likely a key role for RANKL. 
Th   ese data also suggest that progesterone induces cyclin 
D1 independent of RANKL. By contrast, these most 
recent reports [8,9] and others [10] ﬁ   nd that the 
progesterone-dependent induction of cyclin D1 is also 
RANK/RANKL-dependent. Indeed, RANKL also modu-
lates expression of other proliferative cues, including 
cyclin E, Id2, and Id4 [6,7,13], suggesting that multiple 
targets lie downstream of progesterone-induced RANK 
activation. Th   e hierarchy of proliferative pathways within 
mammary epithelial cells that lie downstream of RANKL/
RANK may well prove to be context-speciﬁ  c in terms of 
other regulatory events, including the eﬀ  ects of other 
hormones or growth factors, the extracellular matrix, or 
pregnancy-associated diﬀ   erentiation. Indeed, both 
prolactin and parathyroid hormone-related peptide are 
capable of inducing RANKL in the mammary glands [3] 
while others reported that estrogen was required to 
facilitate progesterone-induced RANKL expression [4].
As pointed out by both groups, the present ﬁ  ndings 
may ﬁ   rmly implicate RANK as a key player during 
progesterone-dependent breast cancer, given that women 
receiving combined estrogen plus progesterone replace-
ment therapy, but not estrogen alone, have an increased 
risk of developing breast cancer [14]. However, any eﬀ  ect 
of progestins such as MPA on breast cancer risk, and 
therefore RANK signaling, presents an opportunity for 
detailed resolution given that MPA at comparable doses 
also serves as the primary progestin in hormonal contra-
ception that has no consistent eﬀ  ect on breast cancer risk 
[15]. Th  erefore, the role of progesterone and RANK/
RANKL during breast cancer onset may well prove to be 
context-speciﬁ   c. Along these lines, diﬀ   erent strains of 
mice respond diﬀ  erently to progesterone in terms of both 
mammary development and RANKL expression [13]. 
Likewise, in both of the present studies the ability of 
RANK to mediate MPA-dependent tumorigenesis was 
enhanced by DMBA that induces a unique mammary 
cancer pathotype distinct from that typical for human 
breast cancer [16].
In conclusion, these important recent ﬁ  ndings  lend 
support to a growing body of data pointing to a key role 
for RANK and its ligand during progestin-dependent 
epithelial proliferation and cancer in the mammary 
glands. Th  ese ﬁ   ndings may prove to be even more 
important for delineating the role of RANK and RANKL 
in managing hormone-dependent and/or -independent 
breast cancer.
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